Navigation Links
Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting

Company-Sponsored Investor Briefing and Webcast to Follow Presentation

DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- Biodel Inc. today announced plans to present clinical results of its leading product candidate, VIAject(TM), at the 67th Annual American Diabetes Association (ADA) Scientific Sessions, to be held in Chicago, June 22 through June 26.

Biodel's oral presentation at the ADA will take place on June 22 from 4:15 - 6:15pm CST, a summary of which will be available on Biodel's website. Following the presentation, the Company will host an investor briefing. Interested parties may access a link to a live audio webcast of the investor briefing in the investor section of Biodel's website at http://www.biodel.com. A replay of the presentation will be available for 14 days.

About Biodel Inc.

Biodel Inc. is a development stage specialty biopharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel develops product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic results. The Company has two insulin product candidates currently in clinical trials for the treatment of diabetes. Additionally, the Company has two preclinical product candidates for the treatment of osteoporosis.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "b elieves," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drugs and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. The Company disclaims any obligation to update any forwa rd-looking statements as a result of events occurring after the date of this press release.

CONTACT: Investors, Clay A. Kramer, , or Media, CarneyNoensie, , both of Burns McClellan, Inc.,+1-212-213-0006, for Biodel Inc. ckramer@burnsmc.com cnoensie@burnsmc.com

Web site: http://www.biodel.com/

Ticker Symbol: (NASDAQ-NMS:BIOD)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... VANCOUVER , March 23, 2017 /PRNewswire/ - INVICTUS ... OTC: IVITF; FRA: 8IS) Invictus MD announces that AB ... crops in its licensed production facility under the Access ... Hamilton, Ontario . ... ACMPR in October 2016, is currently operating at half ...
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... , March 23, 2017 ... Composite ended the trading session at 5,821.64, up ... lower, to finish at 20,661.30; and the S&P ... were broad based as six out of nine ... Stock-Callers.com has initiated reports coverage on the following ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about ... as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is ... for writing, especially about truth and human behavior. , Published by Christian Faith Publishing, ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... A ... bar for entry into teacher preparation programs. The NCTQ report suggests, based on a ... entry requirements would significantly improve teacher quality in the U.S. It argues that this ...
(Date:3/23/2017)... ... 23, 2017 , ... Demonstrating their commitment to improving health ... departments have been awarded national accreditation through the Public Health Accreditation Board ... network of communities across the nation whose health departments meet rigorous national standards ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) ... 10 North Broadway Avenue, will be an educational and exciting program providing busy ... the management of chronic pain. , Oklahoma is in a healthcare crisis. The ...
(Date:3/23/2017)... ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those ... a significant impact on the careers of all others involved. , On Monday, ... into the MBI’s Hall of Fame. The induction took place during the World of ...
Breaking Medicine News(10 mins):